About Affomix
Affomix is a Healthcare company based in New Haven (United States) founded in 2006, and was acquired by Illumina in July 2010. Human monoclonal antibodies are selected using proprietary high-throughput technology. Affomix has raised $7 million across 4 funding rounds from investors including Illumina, Four Seasons and HHS. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its competitors include Avidity Biosciences, Sutro Biopharma and Vividion Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Affomix was founded in 2006 in New Haven, United States, within the biotechnology sector. Proprietary technology is employed for rapid, automated selection of human monoclonal antibodies. Commercialization efforts focus on monoclonal antibodies, microarrays, and libraries applied in research, drug discovery, diagnostics, and therapeutics. Emphasis is placed on measuring large numbers of proteins in biological samples with sensitivity and accuracy. Operations are centered in the United States.
- Headquarters New Haven, United States
- Stage Acquired
- SectorsHealthcare
- Website affomix.com
- Social LinkedIn
- Acquired by Illumina (Jul 2010)
Funding Insights of Affomix
Affomix has successfully raised a total of $7M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $111.35 thousand completed in May 2008. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7M
- Total Rounds 4
- Last Round Grant — $111,350
- First Round $100,000
(Nov 2007)
- Investors Count 4
All 4 funding rounds of Affomix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2008 | $111,350 | Grant | – | – | |
| Jan 2008 | $7M | Series A | – | Connecticut Innovations, Elm Street Ventures | |
| Dec 2007 | $100,000 | Grant | – | – | |
| Nov 2007 | $100,000 | Grant | – | – |
5 investors in total: 5 institutional.
Investors in Affomix
Affomix has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Illumina, Four Seasons and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital services for biotech, IT, and innovative sectors in Connecticut. | ctinnovations.com | |||
VC firm investing in seed & early stage companies in the US | 2006 | elmvc.com | New Haven, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Upscale hotels, resorts, and residential properties are operated globally. | 1961 | fourseasons.com | Toronto, Canada | |
Developer of technologies for analysis of genetic variation and function | 1993 | illumina.com | San Diego, United States |
Investor details for Affomix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Affomix
4 dated milestones of Affomix across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Affomix is founded.
- Funding First funding round of $100K.
- Funding Latest funding round, Grant, of $111K.
- Exit Acquired by Illumina.
Competitors of Affomix
Affomix has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, Sutro Biopharma and Vividion Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform |
Detailed competitors of Affomix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Affomix (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Affomix
Affomix was founded in 2006 and raised its 1st funding round 1 year after it was founded.
Affomix is headquartered in New Haven, United States. It is registered at New Haven, Connecticut, United States.
Affomix is a funded company, having raised a total of $7M across 4 funding rounds to date. The company's 1st funding round was a Grant of $100K, raised on Nov 2007.
Affomix was founded in 2006 in New Haven, United States, within the biotechnology sector. Proprietary technology is employed for rapid, automated selection of human monoclonal antibodies. Commercialization efforts focus on monoclonal antibodies, microarrays, and libraries applied in research, drug discovery, diagnostics, and therapeutics. Emphasis is placed on measuring large numbers of proteins in biological samples with sensitivity and accuracy. Operations are centered in the United States.
Affomix's top competitors include Sutro Biopharma, Avidity Biosciences and Vividion Therapeutics.
Affomix has 5 investors. Key investors include Illumina, Four Seasons, HHS, Elm Street Ventures, and Connecticut Innovations.
Yes. Affomix was acquired by Illumina in July 2010.